10x Genomics, Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Serge Saxonov Ph.D.
- Full Time Employees
- 1,259
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 6230 Stoneridge Mall Road Pleasanton CA United States of America 94588-3260
- IPO Date
- Sep 12, 2019
- CIK
- 0001770787
- Website
- 10xgenomics.com
- Similar Companies
- Business
- 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Company News
10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Cathie Wood dumped Palantir to buy these biotech stocks
Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Torex Gold Provides Q4 2024 Update on Media Luna Project
Cathie Wood's Top Biotech Plays for February
Spatial Omics Research Report 2023-2034: Market to reach $1.09 Billion - 10x Genomics Enhances Spatial OMICS with New Visium Spatial Gene Expression for FFPE
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025
Torex Gold Provides 2025 Operational Guidance and Updated Five-Year Production Outlook
Torex Gold Delivers on Full-Year Production Guidance
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products
Torex Gold to Restart Operations and Project Activities at the Morelos Complex
Torex Gold Receives Notice of Temporary Suspension from the Ministry of Economy
Torex Gold Provides an Update on the Fatalities at ELG Underground